Quantum Biopharma Ltd (QNTM) FinancialsQNTMFinancialQuantum Biopharma Ltd

Evaluating the bottom line, Quantum Biopharma Ltd maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -984.82%, provide a clear picture of how effectively QNTM converts its operational activities into shareholder value.

In the context of the broader market, QNTM competes directly with industry leaders such as QNCX and RNAZ. With a market capitalization of $24.43M, it holds a significant position in the sector. When comparing efficiency, QNTM's gross margin of N/A stands against QNCX's N/A and RNAZ's N/A. Such benchmarking helps identify whether Quantum Biopharma Ltd is trading at a premium or discount relative to its financial performance.

Quantum BioPharma has consistently reported negative net income, with losses increasing over the past quarters, culminating in a loss of $13,560,299 in Q1 2026. The company's EPS has also been negative, with a reported EPS of -3.02 in the latest quarter, indicating ongoing financial struggles.